Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study

MLA

Krebs, Emanuel, et al. “Real-World Cost-Effectiveness of Multi-Gene Panel Sequencing to Inform Therapeutic Decisions for Advanced Non-Small Cell Lung Cancer: A Population-Based Study.” The Lancet Regional Health - Americas, no. Preprints, Jan. 2024. EBSCOhost, https://doi.org/10.1016/j.lana.2024.100936.

APA

Krebs, E., Weymann, D., Ho, C., Bosdet, I., Laskin, J., Lim, H. J., Yip, S., Karsan, A., Hanna, T. P., Pollard, S., & Regier, D. A. (2024). Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study. The Lancet Regional Health - Americas, Preprints. https://doi.org/10.1016/j.lana.2024.100936

Chicago

Krebs, Emanuel, Deirdre Weymann, Cheryl Ho, Ian Bosdet, Janessa Laskin, Howard J. Lim, Stephen Yip, et al. 2024. “Real-World Cost-Effectiveness of Multi-Gene Panel Sequencing to Inform Therapeutic Decisions for Advanced Non-Small Cell Lung Cancer: A Population-Based Study.” The Lancet Regional Health - Americas, no. Preprints (January). doi:10.1016/j.lana.2024.100936.